首页> 外文期刊>Applied Surface Science >Surface plasmon resonance imaging validation of small molecule drugs binding on target protein microarrays
【24h】

Surface plasmon resonance imaging validation of small molecule drugs binding on target protein microarrays

机译:结合在目标蛋白微阵列上的小分子药物的表面等离振子共振成像验证

获取原文
获取原文并翻译 | 示例
           

摘要

Systematic and rapid profiling of the interactions between small molecule drugs (or candidates) and target proteins is vital in studying drug promiscuity and drug discovery. However, a label-free and high-throughput method for the detection of small molecules binding on protein microarray is still lacking. In this research, we introduced surface plasmon resonance imaging (SPRi) technology combined with protein microarray on 3D-dextran hydrogel chip surface to realize the detection of small molecule drugs. With the development and optimization of this method, we obtained the ideal binding signals of small molecular drugs versus their target proteins, with good quality and uniformity (CV = 10.3%, n = 48). Then we demonstrated three applications, including in situ mimicking and detecting the formation of FK506-mediated trimer complex (FKBP12-FK506-calcineurin), rapid validation of FK506-FKBP12 recognition via FKBP12 mutant microarray (1 vs n mode), and 3 x 4 orthogonal studying the drug binding specificity on protein microarray (m vs n mode). Fortunately, these trials enable the label-free and kinetic study of drug-protein interactions on SPRi in a high-throughput manner, which could be a promising solution in screening/forecasting side effect of drugs (or candidates), drug repositioning or repurposing, target identification of natural products and personalized medicine, etc. (C) 2018 Published by Elsevier B.V.
机译:小分子药物(或候选药物)与靶蛋白之间相互作用的系统快速分析对研究药物滥交和药物发现至关重要。但是,仍然缺乏用于检测与蛋白质微阵列结合的小分子的无标记和高通量方法。在这项研究中,我们介绍了表面等离振子共振成像(SPRi)技术与蛋白质微阵列相结合在3D-葡聚糖水凝胶芯片表面上实现小分子药物的检测。随着这种方法的发展和优化,我们获得了小分子药物相对于其靶蛋白的理想结合信号,具有良好的质量和均一性(CV = 10.3%,n = 48)。然后,我们展示了三种应用,包括原位模拟和检测FK506介导的三聚体复合物(FKBP12-FK506-calcineurin)的形成,通过FKBP12突变体微阵列(1对n模式)对FK506-FKBP12识别的快速验证以及3 x 4正交研究在蛋白质微阵列上的药物结合特异性(m vs n模式)。幸运的是,这些试验能够以高通量方式对SPRi上的药物-蛋白质相互作用进行无标记和动力学研究,这可能是筛选/预测药物(或候选药物)副作用,药物重新定位或重新定位,目标识别天然产物和个性化药物等。(C)2018由Elsevier BV发布

著录项

  • 来源
    《Applied Surface Science》 |2018年第30期|328-335|共8页
  • 作者单位

    Chinese Acad Sci, Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, Natl Ctr Nanosci & Technol NCNST, Beijing 100190, Peoples R China;

    Chinese Acad Sci, Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, Natl Ctr Nanosci & Technol NCNST, Beijing 100190, Peoples R China;

    Chinese Acad Sci, Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, Natl Ctr Nanosci & Technol NCNST, Beijing 100190, Peoples R China;

    Chinese Acad Sci, Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, Natl Ctr Nanosci & Technol NCNST, Beijing 100190, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Surface plasmon resonance imaging; Protein microarray; Small molecule drug; Label-free; High-throughput;

    机译:表面等离子体共振成像;蛋白质芯片;小分子药物;无标签;高通量;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号